Guo Yi-qun, Ding Ya, Li Dan-dan, Li Jing-jing, Peng Rui-qing, Wen Xi-zhi, Zhang Xing, Zhang Xiao-Shi
Biotherapy Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
Med Oncol. 2015 Sep;32(9):234. doi: 10.1007/s12032-015-0679-7. Epub 2015 Aug 23.
This study aimed to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. The treatment regimen consisted of nab-paclitaxel (100 mg/m(2)) and carboplatin (area under the curve = 2) administered on days 1 and 8 every 21 days. All of the patients were evaluated on the basis of efficacy and safety in a two-cycle interval. Of the 45 patients, 18 were chemotherapy naive and 27 were chemotherapy treated. Of these cases, 18 manifested acral melanoma and 27 showed non-acral melanomas. Although chemotherapy-naive patients exhibited a higher response to the treatment, similar progression-free survival (PFS) and overall survival (OS) were detected in chemotherapy-naive and chemotherapy-treated patients. A higher response was observed in non-acral melanomas; however, similar PFS and OS occurred between acral and non-acral melanomas. The most common side effects were alopecia, myelosuppression, and gastrointestinal reaction. Nab-paclitaxel combined with carboplatin is a well-tolerated and effective regimen to treat Chinese patients with melanoma, including acral and non-acral melanomas. This treatment may be an alternative approach for Chinese patients with melanoma, especially those without the opportunity to undergo therapy with immune checkpoint inhibitors.
本研究旨在评估纳米白蛋白结合型紫杉醇联合卡铂治疗中国黑色素瘤患者的疗效和安全性。治疗方案为纳米白蛋白结合型紫杉醇（100 mg/m²）和卡铂（曲线下面积 = 2），每21天的第1天和第8天给药。所有患者均以两个周期为间隔对疗效和安全性进行评估。45例患者中，18例为初治化疗患者，27例为经治化疗患者。其中，18例表现为肢端黑色素瘤，27例为非肢端黑色素瘤。虽然初治化疗患者对治疗的反应较高，但初治化疗患者和经治化疗患者的无进展生存期（PFS）和总生存期（OS）相似。非肢端黑色素瘤患者的反应较高；然而，肢端和非肢端黑色素瘤的PFS和OS相似。最常见的副作用是脱发、骨髓抑制和胃肠道反应。纳米白蛋白结合型紫杉醇联合卡铂是一种耐受性良好且有效的治疗方案，可用于治疗中国黑色素瘤患者，包括肢端和非肢端黑色素瘤。对于中国黑色素瘤患者，尤其是那些没有机会接受免疫检查点抑制剂治疗的患者，这种治疗可能是一种替代方法。
